These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8998705)

  • 21. Dopamine agonists in heart failure: an untimely death.
    Smit AJ; Girbes AR
    Neth J Med; 1997 Nov; 51(5):151-3. PubMed ID: 9455093
    [No Abstract]   [Full Text] [Related]  

  • 22. [Strain gauge plethysmography in the evaluation of the effect of acute administration of ibopamine on the peripheral circulation of normal subjects].
    Longhini C; Ansani L; Musacci GF; Fratti D; Toselli T; Lupato L
    Cardiologia; 1982 Dec; 27(12):1189-95. PubMed ID: 6927477
    [No Abstract]   [Full Text] [Related]  

  • 23. New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists.
    Goetz CG
    Exp Neurol; 1997 Mar; 144(1):17-20. PubMed ID: 9126145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dopaminergic stimulation in cardiology: its current status and future strategies].
    Cherchi A; Mercuro G
    Cardiologia; 1987 Dec; 32(12):1631-9. PubMed ID: 3329022
    [No Abstract]   [Full Text] [Related]  

  • 25. [Preliminary results of the action of long-term oral treatment with the di-isobutyric ester of N-methyldopamine (SB 7505) in 10 patients with severe cardiocirculatory decompensation].
    Dei Cas L; Manca C; Mansour M; Vasini G; Zonca A; Bernardini B
    Boll Soc Ital Cardiol; 1980; 25(6):593-600. PubMed ID: 7284164
    [No Abstract]   [Full Text] [Related]  

  • 26. PRIME II (Second Prospective Randomized Study of Ibupamine on Mortality and Efficacy): another disappointment in heart failure therapy.
    Hampton JR
    Eur Heart J; 1997 Oct; 18(10):1519-20. PubMed ID: 9347257
    [No Abstract]   [Full Text] [Related]  

  • 27. Dopamine: pharmacologic and therapeutic aspects.
    Velasco M; Luchsinger A
    Am J Ther; 1998 Jan; 5(1):37-43. PubMed ID: 10099036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopaminergic therapy in acute encephalitis lethargica.
    McAuley J; Shahmanesh M; Swash M
    Eur J Neurol; 1999 Mar; 6(2):235-7. PubMed ID: 10053237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine dysregulation syndrome in a patient with restless legs syndrome.
    Leu-Semenescu S; Karroum E; Brion A; Konofal E; Arnulf I
    Sleep Med; 2009 Apr; 10(4):494-6. PubMed ID: 19410183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sympathomimetic amines: potential clinical applications in ischemic heart disease.
    Goldberg LI; Rajfer SI
    Am Heart J; 1982 Apr; 103(4 Pt 2):724-9. PubMed ID: 6278912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
    Stacy M; Galbreath A
    Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The neurohumoral mechanisms are already altered before the patient may have symptoms of heart failure. Interview by Salvador Giménez].
    López-Sendón JL
    Rev Esp Cardiol; 1993 Jul; 46(7):following 412. PubMed ID: 8101994
    [No Abstract]   [Full Text] [Related]  

  • 35. Are there clinically significant differences between dopamine agonists.
    Stocchi F; Vacca L; Onofrj M
    Adv Neurol; 2003; 91():259-66. PubMed ID: 12442684
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical use of dopamine receptor agonists.
    Murphy MB
    Proc West Pharmacol Soc; 1990; 33():31-5. PubMed ID: 1980363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
    Nutt JG
    Mov Disord; 2007 Jan; 22(1):1-9. PubMed ID: 16958130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of drugs interacting with the dopaminergic receptors on glucose levels and insulin release in healthy and type 2 diabetic subjects.
    Contreras F; Foullioux C; Pacheco B; Maroun C; Bolívar H; Lares M; Leal E; Cano R; Bermúdez V; Velasco M
    Am J Ther; 2008; 15(4):397-402. PubMed ID: 18645345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of docarpamine on hemodynamics after open heart surgery in children.
    Watarida S; Shiraishi S; Sugita T; Katsuyama K; Nakajima Y; Yamamoto R; Yamamoto Y; Imura M; Hirokawa R; Mori A
    Ann Thorac Cardiovasc Surg; 2000 Apr; 6(2):106-9. PubMed ID: 10870004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.